CAR T (Chimeric Antigen Receptor T-Cell Immunotherapy)

序號 論文標題 發表公司

1

Clinical and biologic covariates of outcomes in ZUMA-1: A pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL). (Clinical trial information: NCT02926833)

Kite (KITE.US)

2

Zuma-6: Phase 1-2 multicenter study evaluating safety and efficacy of axicabtagene ciloleucel (axi-cel; KTE-C19) in combination with atezolizumab in patients with refractory diffuse large b-cell lymphoma (DLBCL).  (Clinical trial information:NCT02926833)

Kite (KITE.US)

3

Updated results from ZUMA-3, a phase 1/2 study of KTE-C19 chimeric antigen receptor (CAR) T cell therapy, in adults with high-burden relapsed/refractory acute lymphoblastic leukemia (R/R ALL).  (Clinical trial information: NCT02614066)

Kite (KITE.US)

4

Product characteristics associated with in vivo expansion of anti-CD19 CAR T cells in patients treated with axicabtagene ciloleucel (axi-cel).  (Clinical trial information: NCT02348216)

Kite (KITE.US)

5

Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19).  (Clinical trial information: NCT02348216)

Kite (KITE.US)

6

First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: Updated results. (Clinical trial information: NCT02658929)

Bluebird (BLUE.US)

7

CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T-cell product JCAR017 (TRANSCEND NHL 001).  (Clinical trial information: NCT02631044)

Juno Therapeutics (JUNO.US)

8

Oligoclonal T cells transiently expand and express TIM3 and LAG3 following CD19 CAR T cell therapy. (Clinical trial information: NCT02445248)

Novartis (NVS.US)

資料來源: 2017 ASCO、筆者彙整

喜歡這篇文章嗎?立即分享

你可能感興趣的文章